Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease

causes a difficult-to-treat pulmonary disease (MAb-PD). After initial intravenous treatment, minocycline is recommended in the oral continuation phase of treatment. We determined the MICs, synergy, and time-kill kinetics of minocycline against With MICs of 8 to 512 mg/liter, rapid emergence of toler...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2018-10, Vol.62 (10)
Main Authors: Ruth, Mike M, Sangen, Jasper J N, Pennings, Lian J, Schildkraut, Jodie A, Hoefsloot, Wouter, Magis-Escurra, Cecile, Wertheim, Heiman F L, van Ingen, Jakko
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents
Minocycline
Mycobacterium abscessus
Susceptibility
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:causes a difficult-to-treat pulmonary disease (MAb-PD). After initial intravenous treatment, minocycline is recommended in the oral continuation phase of treatment. We determined the MICs, synergy, and time-kill kinetics of minocycline against With MICs of 8 to 512 mg/liter, rapid emergence of tolerance in time-kill assays, and no synergy with other drugs used to treat MAb-PD, minocycline appears ineffective against These data question its role as a MAb-PD treatment modality.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.01208-18